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Abstract
Purpose: The purpose of this study was to compare the prostate contours drawn by two radiation oncologists and 
one radiologist on magnetic resonance (MR) and transrectal ultrasound (TRUS) images. TRUS intra- and inter-fraction 
variability as well as TRUS vs. MR inter-modality and inter-operator variability were studied. 
Material and methods: Thirty patients affected by localized prostate cancer and treated with interstitial high-dose-
rate (HDR) prostate brachytherapy at the National Cancer Institute in Milan were included in this study. Twenty-five 
patients received an exclusive two-fraction (14 Gy/fraction) treatment, while the other 5 received a single 14 Gy fraction 
as a boost after external beam radiotherapy. The prostate was contoured on TRUS images acquired before (virtual US) 
and after (real US) needle implant by two radiation oncologists, whereas on MR prostate was independently contoured 
by the same radiation oncologists (MR1, MR2) and by a dedicated radiologist (MR3). Absolute differences of prostate 
volumes (│∆V│) and craniocaudal extents (│∆dz│) were evaluated. The Dice’s coefficient (DC) was calculated to quan-
tify spatial overlap between MR contours. 
Results: Significant difference was found between Vvirtual and Vlive (p < 0.001) for the first treatment fractions and 
between VMR1 and VMR2 (p = 0.043). Significant difference between cranio-caudal extents was found between dzvirtual and 
dzlive (p < 0.033) for the first treatment fractions, between dzvirtual of the first treatment fractions and dzMR1 (p < 0.001) 
and between dzMR1 and dzMR3 (p < 0.01). Oedema might be responsible for some of the changes in US volumes. Aver-
age DC values resulting from the comparison MR1 vs. MR2, MR1 vs. MR3 and MR2 vs. MR3 were 0.95 ± 0.04 (range, 
0.82-0.99), 0.87 ± 0.04 (range, 0.73-0.91) and 0.87 ± 0.04 (range, 0.72-0.91), respectively. 
Conclusions: Our results demonstrate the importance of a multiprofessional approach to TRUS-guided HDR pros-
tate brachytherapy. Specific training in MR and US prostate imaging is recommended for centers that are unfamiliar 
with HDR prostate brachytherapy.
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Purpose
High-dose-rate (HDR) brachytherapy (BT) as mono-
therapy or as a boost (i.e., combined with external beam 
radiotherapy) has been described in many prostate cancer 
trials showing a good clinical outcome and a favourable 
toxicity profile [1]. Ten-year long-term data of low- or 
intermediate-risk patients have proved a durable disease 
control in terms of biochemical disease-free survival and 
low toxicity [2]. According to mono-institutional studies 
with a median follow-up time up to 8 years, HDR-BT has 
also resulted in effective and safe in treating of intermediate- 
or high-risk patients [3,4].
Our HDR-BT experience started in December 2009 
and was preceded by a preliminary period including at-
tendance of both general and specific prostate courses as 
well as on-site visits to radiotherapy centres with long-
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time experience in BT (greater than 10 years). Concerning 
dose fractionation, we referred to Morton’s and Martinez’s 
experiences [5,6]. Our objective was to perform a limited 
number of implants (i.e., 1 implant for boosts, 2 implants 
for monotherapies), and remove needles after each treat-
ment session. We chose trans-rectal ultrasound (TRUS) im-
aging with intra-operative on-line treatment planning [7], 
to have a real time vision of the needle implant and patient 
position without moving the patient to the computed to-
mography (CT) or magnetic resonance (MR) scanner [8,9] 
thus avoiding possible risk of implant dislocation.
TRUS imaging is used to define treatment feasibility 
(according to GEC ESTRO patient selection criteria, up-
dated by Hoskin et al. [10,11]) and is essential for prostate, 
seminal vesicles, bladder, rectum, and urethra contour-
ing for treatment planning. Nevertheless, at our institu-
tion, radiation oncologists (ROs) did not have any direct 
experience in ultrasound imaging and they underwent 
a preliminary coaching period of 3 months, once a week, 
with our ultrasound radiologists. Now, after a few years 
of experience, we decided to investigate the ability of our 
ROs to accurately contour the prostate on MR and TRUS 
images and to see how far they still are from the contour-
ing performed by a dedicated radiologist.
The purpose of this study was to compare the contours 
of the prostate performed by two ROs and one radiologist 
on MR and TRUS images. TRUS intra- and inter-fraction 
variability as well as TRUS vs. MR inter-modality vari-
ability and inter-operator variability were studied.
Material and methods
Patient and treatment characteristics
Thirty patients affected by localized prostate cancer 
and treated with interstitial HDR prostate brachytherapy 
at the National Cancer Institute in Milan were included 
in this study. All the cases were proposed to brachythera-
pists after a multidisciplinary 1st visit (including surgeon, 
radiation oncologist and medical oncologist) during 
which patients are presented with the various therapeu-
tic options. Age of the participants ranged from 56 to 
81 years; mean and median ages were 69 and 70 years, 
respectively. Distribution according to 2009 TNM stage 
(7th edition) was as follows: T1c 23; T2a 3; T2b 3; T3a 1. 
For staging purposes, all patients underwent endo rectal 
coil MR imaging with the following sequence: fast spin-
echo T2-weighted (1.5 T), repetition time 3,360 ms, echo 
time 126 ms, slice thickness 3 mm, interslice gap 0.3 mm.
All patients underwent transrectal ultrasound imaging 
at first visit in the BRT office for feasibility evaluation of 
the brachytherapy treatment. Patients eligibility criteria 
were selected according to the GEC ESTRO 2013 update 
[11]; in particular, patients were eligible if there were no 
problems with probe introduction (e.g. anorectal stenosis), 
if the visibility of prostate boundaries was adequate, if the 
pubic arch was not interfering with needles implantation, 
if prostate volume was below 60 cc and if urethra anatomy 
was acceptable (e.g., no kinking or severe phimosis). 
US imaging was performed with a Pro Focus Ultra-
sound System provided with TRUS probe (type 8848, BK 
Medical Systems, Herlev, Denmark). The TRUS probe 
was mounted on a stepper which allowed acquisition of 
axial images of the prostate every 1 mm. A specific QA of 
the TRUS system is routinely performed at our hospital 
according to the AAPM TG-128 Report [12], and the CIRS 
45 phantom (Computerized Imaging Reference Systems, 
Norfolk (VA), USA) is used to perform this task.
Twenty-five patients received an exclusive two-frac-
tion (14 Gy/fraction) treatment, while the other 5 received 
a single 14 Gy fraction as a boost after external beam ra-
diotherapy (50 Gy, 25 fractions). Eleven patients had 
neo-adjuvant androgen deprivation (NAAD) and 5 pa-
tients had adjuvant androgen deprivation (AAD). During 
each treatment fraction, patients underwent TRUS imag-
ing both before (virtual US) and after needle implanta-
tion (live US) (Figure 1), according to the procedure of 
Fig. 1. Example of a virtual ultrasound image (i.e., before needle implantation) and live ultrasound image (i.e., after needle im-
plantation) 
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TRUS-based real-time treatment planning exhaustive-
ly described elsewhere [6]. The treatment was planned 
in real-time on the live US images and performed with 
a remote afterloader device provided with 192Ir source 
(micro Selectron HDR, Nucletron Elekta, Veenendaal, 
The Netherlands). 
All cases were re-contoured for the study months to 
years after the actual treatment procedure by 2 ROs, sep-
arately. Live contours were made after virtual contours 
with an adaptation process, mimicking the actual treat-
ment procedure.
Evaluation and comparison of prostate volume 
and craniocaudal dimension
Although the American Institute of Ultrasound in 
Medicine (AIUM) has developed practice parameter for 
the performance of an ultrasound evaluation of the pros-
tate (and surrounding structures), to the best of our knowl-
edge no specific guidelines are available for manual (i.e., 
non automated) prostate segmentation in HDR-BT [13]. 
Pelvic male normal tissue contouring guidelines for radi-
ation therapy have been produced by the Radiation Ther-
apy Oncology Group (RTOG) applying to CT scans [14]; 
prostate contouring errors and methods to improve pros-
tate contouring accuracy were reported by Mc Laughlin 
et al. [15]. As for MR, an atlas of T2 MR prostate anatomy 
with CT correlation is available as a web resource [16]; 
some papers on prostate magnetic resonance imaging for 
brachytherapists were published recently by Soni, Ven-
katesan et al. [17,18,19].
The prostate was contoured on US and MR images by 
means of the treatment planning system (TPS) Oncentra 
Prostate ver. 3.3 (Nucletron Elekta, Veenendaal, The Neth-
erlands) and the MIM® software (version 6.5.6, MIM Soft- 
ware Inc, Cleveland, Ohio, USA), respectively. As com-
monly done at our institution, US images were contoured 
by two radiation oncologists working together and provid-
ing one contouring result. On the contrary, MR images were 
independently contoured by the same two radiation oncol-
ogists, hereafter called MR1 and MR2. MR images were also 
contoured by a dedicated radiologist, hereafter MR3.  
The volume (V) and the cranio-caudal extent (d) of the 
prostate were collected and compared. V was automati-
cally quantified on US and MR images by the TPS and the 
MIM software, respectively. On US images, d was calcu-
lated multiplying the number of contoured images by the 
slice thickness. Whereas, on MR images, it was calculated 
multiplying the number of images by the slice thickness, 
including the gap between slices. The following contour-
ing sets were compared (Figure 2): i) virtual vs. live US, 
for both fractions (i.e., TRUS intra-fraction comparison), 
ii) I fraction virtual/live vs. II fraction virtual/live US, 
in case of exclusive treatments (i.e., TRUS inter-fraction 
comparison); iii) MR1 vs. I fraction virtual US (i.e., inter- 
modality comparison); iv) MR1 vs. MR2 (i.e., inter-oper-
ator comparison) and v) MR1/MR2 vs. MR3 (i.e., inter- 
professional comparison).
Statistical analysis
The statistical significance of the differences between 
volumes and cranio-caudal extents of different contour-
ing sets was assessed with the Wilcoxon test for paired 
samples. A p-value < 0.05 was considered significant. 
The test was performed using the software Statistica ver-
sion 12 (StatSoft, Tulsa, OK, USA). Average and standard 
deviation of prostate volumes and of prostate cranio-cau-
dal extents were also calculated for every set of contours. 
MR1, MR2 and MR3 contours were superimposed in 
order to investigate in which prostate regions the differ-
ences between those contours were more considerable. 
In fact prostate volume alone is not a sufficient indicator 
of similarity: two contours could only partially overlap 
even if they have similar volumes. Dice’s coefficients 
(DCs) were calculated for every combination of prostate 
contours drawn on MR images (MR1 and MR2, MR1 and 
MR3, MR2 and MR3) as a more specific indicator of sim-
ilarity. Considering two volumes A and B, DC is defined 
as the intersection volume divided by the average vol-
ume, according to DC = 2 (A∩B)/(A+B).
Results
Tables 1 and 2 show average prostate volumes <V> and 
cranio-caudal extents <d> calculated from the acquired im-
ages. The p-values for the different performed comparisons 
are shown. A significant difference was found between 
Vvirtual and Vlive (p < 0.001) for the first treatment fractions, 
with Vlive > Vvirtual in 23 out of 30 cases, and between VMR1 
and VMR2 (p = 0.043), with VMR1 > VMR2 in 21 out of 30 cas-
es. Regarding the cranio-caudal extents, a significant dif-
ference was found between dzvirtual and dzlive (p < 0.033) 
for the first treatment fractions (i.e., dzlive ≥ dzvirtual in 26 
out of 30 cases), between dzvirtual of the first treatment frac-
tions and dzMR1 (p < 0.001) with dzvirtual ≤ dzMR1 in 27 out 
Virtual TRUS Live TRUS MR1 MR2 MR3
1st fraction (overall: 25 + 5 pts)
1st fraction (25 pts)
2nd fraction (25 pts)
3
4
5
5
2 2
1
1
Fig. 2. Schematic representation of the different comparisons between contouring sets performed in this study
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of 30 cases, and between dzMR1 and dzMR3 (p < 0.01), with 
dzMR1 > dzMR3 in 16 out of 30 cases. It must be however 
noted that the analysis of difference between dzvirtual and 
dzMR1 might be partially inaccurate, because the patient is 
unlikely to be in the same position for both MR and US 
scans, and the scanning plane is therefore unlikely to be 
the same.
Average DC values resulting from the comparison MR1 
vs. MR2, MR1 vs. MR3 and MR2 vs. MR3 were 0.95 ± 0.04 
(range 0.82-0.99), 0.87 ± 0.04 (range 0.73-0.91) and 0.87 ± 0.04 
(range 0.72-0.91), respectively. TRUS vs. MR intermodali-
ty comparison was not possible for one patient, who un-
derwent hormonal therapy for prostate volume reduction 
after MR imaging and before the brachytherapy treatment.
Discussion
A trend towards higher live volumes in the first treat-
ment fraction was observed. However, the number of 
cases in which volume differences are higher than 10% 
is limited. This means that the volumes contoured in the 
second part of the procedure (i.e., after needle implan-
tation, therefore in a more difficult visual condition) are 
systematically bigger than those contoured in the first 
part of the procedure (i.e., on which the pre-planning is 
Table 1. Average prostate volumes <V> with standard deviations (k = 1) and ranges calculated on ultrasound 
(US) and magnetic resonance images. The range of the differences between the analysed images is also pro-
vided. Regarding US images belonging to the first treatment fractions, average values were calculated both 
for all 30 patients and also for the subset of 25 patients who underwent brachytherapy as a two-fraction 
monotherapy treatment
Images n pts <V> (cm3) Range (cm3) Statistical differences Range of differences (cm3)
I fraction virtual US 30 32.7 ± 8.8  13.4-56.3
I fraction live US 30 33.7 ± 8.7  13.5-56.6 p < 0.001 (1a) (–3.7-4.0) (1a)
I fraction virtual US 25* 34.4 ± 8.0  21.9-56.3
I fraction live US 25* 35.5 ± 7.8  23.4-56.6 
II fraction virtual US 25 34.0 ± 7.0  21.9-45.6 p = 0.58 (2a) (–10.7-10.3) (2a)
II fraction live US 25 34.3 ± 6.6 23.0-48.0 p = 0.46 (1b); p = 0.78 (2b) (–3.1-6.0) (1b)
(–11.9-10.0) (2b)
MR1 30 34.4 ± 11.8  14.4-77.0 p = 0.48 (3) (–6.5-16) (3)
MR2 30 33.9 ± 10.9  17.9-71.9 p = 0.043 (4)
MR3 30 33.3 ± 10.9  11.1-65.5 p = 0.33 (5a); p = 0.61 (5b)
*These 25 patients represent a subset of the 30 patients above, who underwent brachytherapy as a two-fraction monotherapy treatment and could be com-
pared with the II fraction virtual and live US. (1a) – I fraction virtual vs. live US, (1b) – II fraction virtual vs. live US, (2a) – I fraction virtual vs. II fraction virtual US, 
(2b) – I fraction live vs. II fraction live US, (3) – MR1 vs. I fraction virtual US, (4) – MR1 vs. MR2, (5a) – MR1 vs. MR3, (5b) – MR2 vs. MR3. In bold, p values smaller than 
0.05. US – ultrasonography, MR – magnetic resonance
Table 2. Average prostate cranio-caudal extension <d> with standard deviations (k = 1) and ranges calcula-
ted on ultrasound (US) and magnetic resonance images. The range of the differences between the analysed 
images is also provided. Regarding US images belonging to the first treatment fractions, average values were 
calculated both for all 30 patients and also for the subset of 25 patients who underwent brachytherapy as 
a two-fraction monotherapy treatment
Images n pts <dz> (mm) Range (mm) Statistical differences Range of differences (mm)
I fraction virtual US 30 36.9 ± 6.4  26-55
I fraction live US 30 37.8 ± 5.8  27-55 p = 0.033 (1a) (–3-6) (1a)
I fraction virtual US 25* 37.6 ± 6.5  26-55
I fraction live US 25* 38.5 ± 5.8  30-55
II fraction virtual US 25 37.2 ± 4.2  29-48 p = 0.68 (2a) (–6-10) (2a)
II fraction live US 25 37.8 ± 4.3  29-48 p = 0.19 (1b); p = 0.79 (2b) (–6-5) (1b)
(–8-8) (2b)
MR 1 30 45.2 ± 7.8  29.7-62.7 p < 0.001 (3) (–5.7-16.1) (3)
MR 2 30 45.1 ± 6.5  33.0-59.4 p = 0.63 (4)
MR 3 30 43.1 ± 7.2  26.4-59.4 p < 0.01 (5a); p = 0.09 (5b)
*These 25 patients represent a subset of the 30 patients above, who underwent brachytherapy as a two-fraction monotherapy treatment and could be com-
pared with the II fraction virtual and live US. (1a) – I fraction virtual vs. live US, (1b) – II fraction virtual vs. live US, (2a) – I fraction virtual vs. II fraction virtual US, 
(2b) – I fraction live vs. II fraction live US, (3) – MR1 vs. I fraction virtual US, (4) – MR1 vs. MR2, (5a) – MR1 vs. MR3, (5b) – MR2 vs. MR3. In bold, p values smaller than 
0.05. US – ultrasonography, MR – magnetic resonance
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based), but the differences between the volumes are gen-
erally limited. The same trend was observed in the first 
treatment fraction for the cranio-caudal extent, with larg-
er values for live contouring compared to those obtained 
in virtual contouring. Only in few cases, the difference 
was greater than 3 mm.
As reported before, live contours were carried out 
starting from virtual image contours and adapting them to 
the new images. Even if a good initial overlap is possible 
by means of small rigid roto-translations, according to our 
experience it is necessary to review the target contour on 
every image in order to properly correct it to the new live 
image. It must be stressed that implanted needles produce 
image artifacts which make this task particularly difficult. 
In cases of doubt, a larger live volume is likely contoured 
by the observer as his/her conservative choice to not leave 
any region of the prostate uncovered by the treatment 
dose. Moreover, it is also well known that the prostatic 
gland might suffer moderate volumetric/dimensional 
modifications occurring during/after needle implanta-
tion. These modifications, which typically are its swelling 
caused by the edema produced by the needles, might have 
had an impact on the resulting difference between virtual 
and live targets [20,21].
With respect to the comparison between volumes 
and cranio-caudal extents drawn in the first and second 
treatment fractions, no significant differences resulted 
both in pre-planning and final contouring. Considering 
a mean time interval of about one month between first 
and second treatment fraction, this finding excludes an 
important prostate edema or at least its persistence in 
the second treatment fraction. This is in line with the 
results published for low-dose-rate brachytherapy treat-
ments with permanent radioactive seeds, where prostate 
post-implant acute edema was found to resolve within 
about 1 month [22]. 
Prostate gland dissolves in the apex area and connects 
with the bladder wall in the base area. For this reason, even 
if US imaging is a very accurate imaging modality, it is 
undeniable that prostate contouring on US images is a de-
manding task. MR images available before intervention 
help to appreciate with greater accuracy the prostate anat-
omy, in particular those regions that are most difficult to 
be discriminated from the surrounding soft tissues on US 
images. Differences are predominant in the apex and the 
base regions [23,24], but on the average they don’t result 
in significant differences between the contoured volumes.
It must be however noted that US and MR images do 
not perfectly overlap because the prostate is differently 
deformed by the two endo-rectal probes. In fact, US and 
MR probes have different diameters (i.e., 2 cm for TRUS 
and up to 5 cm for MR), are used on patients positioned 
differently (i.e., lithotomy position for TRUS and prone po-
sition for MR) and provide different directional pressures. 
The prostate gland is therefore more compressed on MR 
images, with a reduced antero-posterior and an increased 
cranio-caudal extent. In addition to the different apex and 
base evaluation capability, this instrumental difference 
possibly explains the significantly longer cranio-caudal 
prostate extents on MR images. Nevertheless, differences 
between the two imaging modalities do not compromise 
the advantage of detailed anatomical information in MR 
images (e.g., apex and base structures, adenomatous pros-
tatic hypertrophy, transurethral prostatic resections out-
comes). The use of deformable image registration tools 
would probably help to improve quality of image registra-
tion [24,25], however study of such tools was beyond the 
purposes of this work. 
Comparison between contours drawn by two radiation 
oncologists on MR images aimed to investigate if prostate 
anatomy interpretation was similar between the two ob-
servers. It resulted that the first observer (MR1) identified 
a prostate volume that was significantly bigger than the 
one contoured by the second observer (MR2). Being how-
ever the average DC of the comparison between the two 
sets of volumes very high, it results that the overall pros-
tate shapes identified by MR1 and MR2 are usually similar, 
with MR1 being less tight to the observed prostate edge 
than MR2. Interestingly, comparison with the contours 
drawn by a dedicated radiologist (MR3) resulted in differ-
ences between overall volumes that were not significant. 
However, local differences between the contours were ap-
preciated, in particular in correspondence to the apex and 
base. Both radiation oncologists generally seemed to expe-
rience the same contouring difficulties and agreed more 
with each other (i.e., DC = 0.95) than with the radiologist 
(i.e., DC = 0.87 for both MR1 and MR2).
Figure 3 shows examples of possible critical regions 
of the prostate that were differently contoured by the 
three physicians. In general, radiologist identified shorter 
extensions of the prostate, with dMR3 being significantly 
lower than dMR1.
Fig. 3. Examples of regions of the prostate that were critical to be contoured accurately. From left to right: apex, base, and plexus. 
Red, green, and purple contours refer to MR1, MR2, and MR3, respectively
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Conclusions
No important volume differences resulted between the 
first and the second treatment fractions. The time gap be-
tween the two treatments was one month, apparently long 
enough for the resolution of possible post-implant acute 
edema. Also, virtual US and pre-implant MR volumes re-
sulted relatively similar one to each other, despite differ-
ent patient positioning and endorectal probes. The greater 
craniocaudal extents in MR images were most probably 
due to the stronger pressure on the prostate exerted by the 
endorectal coil. 
Results of this study demonstrate the importance of 
a multiprofessional approach to TRUS-guided HDR-BT 
treatments of the prostate. A specific training in MR and 
US prostate imaging is recommended for centers that 
are not familiar with HDR prostate brachytherapy treat-
ments. In the daily practice, even if radiation oncologists 
are expert in their field, we recommend to contour the 
pretreatment US and staging MR images and then to re-
view them together with a radiologist, so to minimize 
contouring inaccuracies during the real treatment. Final-
ly, in light of image quality detriment after the implant, 
due to needle artifacts, close attention is needed to adapt, 
slice by slice, virtual contours to live images.
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